Ovarian Cancer: Evolving Concepts Around Systemic Therapy

home / peer-exchange / evolving-concepts-around-systemic-therapy

GOG-0218: Frontline Bevacizumab in Ovarian Cancer

EP. 1: GOG-0218: Frontline Bevacizumab in Ovarian Cancer

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

SOLO-1: Frontline Olaparib Maintenance Therapy in Ovarian Cancer

EP. 2: SOLO-1: Frontline Olaparib Maintenance Therapy in Ovarian Cancer

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer

EP. 3: PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

Practical Applications of PRIMA in Ovarian Cancer Management

EP. 4: Practical Applications of PRIMA in Ovarian Cancer Management

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

PAOLA-1: Combination Maintenance Therapy in Ovarian Cancer

EP. 5: PAOLA-1: Combination Maintenance Therapy in Ovarian Cancer

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

Ovarian Cancer: Factors in Deciding on Maintenance Therapy

EP. 6: Ovarian Cancer: Factors in Deciding on Maintenance Therapy

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

Ovarian Cancer: What is the Role of HRD Testing?

EP. 7: Ovarian Cancer: What is the Role of HRD Testing?

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

Treating Ovarian Cancer Based on HRD Status

EP. 8: Treating Ovarian Cancer Based on HRD Status

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

Ovarian Cancer: Updates to NCCN Guidelines

EP. 9: Ovarian Cancer: Updates to NCCN Guidelines

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

Ovarian Cancer: Maintenance Following Frontline Bevacizumab

EP. 10: Ovarian Cancer: Maintenance Following Frontline Bevacizumab

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

Considerations for the JAVELIN OVARIAN 100 Study

EP. 11: Considerations for the JAVELIN OVARIAN 100 Study

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

Frontline Ovarian Cancer Management: Ongoing Clinical Trials

EP. 12: Frontline Ovarian Cancer Management: Ongoing Clinical Trials

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

PARP Inhibition’s Role in Recurrent Ovarian Cancer

EP. 13: PARP Inhibition’s Role in Recurrent Ovarian Cancer

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

Recurrent Ovarian Cancer: Choosing a PARP Inhibitor

EP. 14: Recurrent Ovarian Cancer: Choosing a PARP Inhibitor

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

Bevacizumab’s Role in Recurrent Ovarian Cancer

EP. 15: Bevacizumab’s Role in Recurrent Ovarian Cancer

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

Recurrent Ovarian Cancer: Novel Agents Under Investigation

EP. 16: Recurrent Ovarian Cancer: Novel Agents Under Investigation

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

Novel Combination Strategies in Recurrent Ovarian Cancer

EP. 17: Novel Combination Strategies in Recurrent Ovarian Cancer

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

Systemic Management of Ovarian Cancer: Closing Thoughts

EP. 18: Systemic Management of Ovarian Cancer: Closing Thoughts

By Bradley J. Monk, MD, Creighton University School of Medicine
Thomas J. Herzog, MD

Latest Conference Coverage

Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer

As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.